November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
November 17, 2024 — By 38%, Tirzepatide cuts the risk of bad outcomes in persons with obesity and an increasingly common form of heart failure that obesity causes. The diagnosis is heart failure with preserved ejection fraction or HFpEF. The measure of bad outcomes it prevents was a composite worsening heart failure or death from cardiovascular disease. Worsening heart […]
September 4, 2024 — If nothing else, the ESC (European for Cardiology) Congress in London this week made one thing clear – everyone in mainstream medicine is now ready to claim the disease of obesity. Cardiologists all over the world are adopting a view we’ve been espousing here for decades. Obesity is not a lifestyle. Not a behavioral problem. […]
August 24, 2024 — Novo Nordisk is creeping up on an indication for semaglutide in people with obesity and heart failure. Today in Lancet, we have another piece of the puzzle to suggest this drug might help. In a prespecified analysis from the SELECT study, researchers found that semaglutide reduced heart attacks, strokes, deaths, and problems with heart failure […]
May 14, 2024 — How long? So many questions about advanced obesity medicines center on this line of inquiry. How long must I take these medicines, how long will their benefits last. Yesterday we learned at ECO2024 that four years of semaglutide offers impressive benefits for a person’s weight and heart health. Nature Medicine published data on weight outcomes […]
March 9, 2024 — It’s official. FDA now says that semaglutide, in doses used to treat obesity, can prevent heart attacks, strokes, and deaths in persons with cardiovascular disease and overweight or obesity. This is nothing short of the dawn of a new era in obesity treatment. FDA Division Director John Sharretts said it clearly: “This patient population has […]
December 28, 2023 — This was a year of great progress in obesity, and with that progress came frustrations and angst. So finding the best and worst of 2023 in obesity and health is actually quite an easy and interesting task. Let’s dig right in. #1 Best: Cardiovascular Outcomes Benefit Data for Semaglutide Above all else the landmark findings […]
November 16, 2023 — It was an amazing moment. Hundreds upon hundreds people packed into huge convention hall to hear about the detailed outcomes of the first ever randomized controlled trial to show that treating obesity could prevent heart attacks, strokes, and cardiovascular deaths. The implications of the SELECT trial for obesity care will be enormous and we had […]
November 12, 2023 — For some time to come, we will be learning more and more about the details and implications of the landmark SELECT study published yesterday in NEJM and presented at the American Heart Association Scientific Sessions in Philadelphia. A massive crowd packed the meeting hall yesterday for good reason. These results will change the practice of […]
November 11, 2023 — Newly published in full, the results of the SELECT study of semaglutide for cardiovascular outcomes in persons with obesity but not diabetes makes one thing undeniable. Obesity is a chronic, treatable disease. Treating obesity requires more than just telling a person to change their lifestyle. It involves addressing the disease pathology that is at work, […]
